Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.55 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.49 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.49 |
| ▸ | TK2 | O00142 | 2/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18503571 | 1.00 | PYGM (0.55) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18512964 | 1.00 | PYGM (0.55) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL26369667 | 1.00 | PYGM (0.55) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL1965361 | 1.00 | PYGM (0.55) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18512965 | 1.00 | PYGM (0.55) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL23883104 | 0.91 | PYGM (0.53) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL11883660 | 0.90 | PYGM (0.57) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL26370134 | 0.90 | CDA (0.46) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL30130603 | 0.89 | PYGM (0.56) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL11877280 | 0.89 | PYGM (0.56) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3267 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109727-A1 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2026-04-23 | — | — | US | claimed |
| EP-4705468-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | California Institute of Technology (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250295744-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS | BioNTech SE (DE) | 2025-09-25 | — | — | US | claimed |
| US-20250277223-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES | IMCYSE SA (BE) | 2025-09-04 | — | — | US | claimed |
| EP-4598935-A2 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2025-08-13 | — | — | EP | claimed |
| WO-2025137275-A1 | NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME | MODERNATX, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129186-A1 | CLOSTRIDIOIDES DIFFICILE VACCINE AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-06-19 | — | — | WO | claimed |
| EP-4565692-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| CN-110719787-A | RNA for treating autoimmune diseases | 生物技术RNA制药有限公司 | 2020-01-21 | — | — | CN | claimed |
| EP-3387150-B1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2019-10-02 | — | — | EP | claimed |
| WO-2018188730-A1 | RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2018-10-18 | — | — | WO | claimed |
| WO-2018189193-A1 | RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2018-10-18 | — | — | WO | claimed |
| EP-3387150-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | Novartis AG (CH) | 2018-10-17 | — | — | EP | claimed |
| US-9719084-B2 | Co-transcriptional assembly of modified RNA nanoparticles | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2017-08-01 | — | — | US | claimed |
| WO-2017098468-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2017-06-15 | — | — | WO | claimed |
| US-20150203842-A1 | CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | 2015-07-23 | — | — | US | claimed |
| WO-2014039809-A2 | CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2014-03-13 | — | — | WO | claimed |
| EP-2578685-A2 | RNA containing modified nucleosides and methods of use thereof | The Trustees of The University of Pennsylvania (US) | 2013-04-10 | — | — | EP | claimed |